Clinical Trial Update: Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Chlorproguanil-Dapsone-Artesunate (CDA) to Chlorproguanil-Dapsone (LAPDAP) for uncomplicated falciparum malaria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Falciparum Malaria
• Malaria

Drugs mentioned

• Chlorproguanil-Dapsone-Artesunate (Chlorproguanil-Dapsone-Artesunate)
• Lapdap (chlorproguanil-dapsone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria, Falciparum | Phase 3 | Status: COMPLETED